Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 3,801 Shares of Company Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Chapman sold 3,801 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $411.80, for a total value of $1,565,251.80. Following the completion of the transaction, the chief executive officer directly owned 87,431 shares in the company, valued at $36,004,085.80. The trade was a 4.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, October 28th, Steven Chapman sold 3,430 shares of Natera stock. The stock was sold at an average price of $426.34, for a total transaction of $1,462,346.20.
• On Tuesday, October 27th, Steven Chapman sold 2,264 shares of Natera stock. The shares were sold at an average price of $406.00, for a total transaction of $919,184.00.
• On Thursday, October 1st, Steven Chapman sold 1,273 shares of Natera stock. The shares were sold at an average price of $413.31, for a total value of $526,143.63.
• On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The stock was sold at an average price of $320.99, for a total transaction of $545,041.02.

Natera Price Performance

NASDAQ NTRA opened at $391.03 on Thursday. The firm has a market capitalization of $56.36 billion, a price-to-earnings ratio of -287.52 and a beta of 1.55. The company’s fifty day moving average is $380.30 and its two-hundred day moving average is $268.64. Natera, Inc. has a 52-week low of $181.00 and a 52-week high of $437.41.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. Natera’s quarterly revenue was up 37.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.74) earnings per share. As a group, sell-side analysts expect that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Medicare coverage for Signatera in HCC could improve patient access and support adoption of Natera’s cancer-monitoring tests. The coverage milestone adds to the commercial opportunity for its oncology business. Natera Medicare coverage for Signatera in HCC
• Positive Sentiment: New ESMO oncology evidence was described as broadening the case for Natera’s cancer-testing portfolio, potentially reinforcing the longer-term growth story. ESMO data broaden Natera’s oncology case
• Neutral Sentiment: Natera was expected to report earnings on November 5, making results and management’s outlook a near-term catalyst; the preview article did not provide reported results. Natera earnings preview
• Neutral Sentiment: The reported analyst consensus price target was $394.31, close to the share price cited in the provided market background, suggesting limited implied upside from that target alone. Natera consensus target price
• Neutral Sentiment: CFO Michael Brophy sold 1,178 shares under a pre-arranged Rule 10b5-1 plan and retained 48,480 shares. The scheduled nature and relatively small size of the sale may temper its significance as a signal about management’s outlook. CFO share sale report

Institutional Investors Weigh In On Natera

A number of hedge funds have recently added to or reduced their stakes in NTRA. Trust Co. of Vermont bought a new stake in shares of Natera during the 2nd quarter valued at $26,000. Elevation Wealth Partners LLC acquired a new position in shares of Natera in the 2nd quarter valued at $30,000. Continuum Advisory LLC bought a new position in shares of Natera in the 2nd quarter worth $33,000. Rakuten Securities Inc. bought a new position in shares of Natera in the 2nd quarter worth $35,000. Finally, Burkett Financial Services LLC acquired a new stake in shares of Natera during the third quarter worth $57,000. Institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent analyst reports. Royal Bank Of Canada boosted their price target on shares of Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a research report on Friday, September 25th. Roth Capital started coverage on Natera in a report on Thursday, October 22nd. They issued a “buy” rating and a $475.00 target price on the stock. Barclays increased their price target on Natera from $340.00 to $475.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Morgan Stanley increased their price target on Natera from $355.00 to $435.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Finally, Robert W. Baird set a $348.00 price target on Natera in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average price target of $394.31.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.